Unipolare Depression Langfassung - Versorgungsleitlinien.de

32. Kirsch I, Sapirstein G. Listening to prozac but hearing placebo: A meta-analysis of
antidepressant medication. Prev Treatm 1998;1(1).
33. Kirsch I, Moore TJ, Scoboria A. The emperor's new drugs: An analysis of antidepressant
medication data submitted to the U.S. Food and Drug Administration. Prev Treatm 2002;5.
34. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity
and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug
Administration. PLoS Med 2008;5(2):e45.
35. Moncrieff J, Kirsch I. Efficacy of antidepressants in adults. BMJ 2005;331(7509):155-7.
36. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of
antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008;358(3):252-60.
37. Moncrieff J, Wessely S, Hardy R. Active placebos versus antidepressants for depression.
Cochrane Database Syst Rev 2004;(1):CD003012.
38. Walsh BT, Seidman SN, Sysko R, Gould M. Placebo response in studies of major depression:
variable, substantial, and growing. JAMA 2002;287(14):1840-7.
39. Khan A, Warner HA, Brown WA. Symptom reduction and suicide risk in patients treated with
placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration
database. Arch Gen Psychiatry 2000;57(4):311-7.
40. Geddes JR, Carney SM, Davies C, Furukawa TA, Kupfer DJ, Frank E, Goodwin GM. Relapse
prevention with antidepressant drug treatment in depressive disorders: a systematic review.
Lancet 2003;361(9358):653-61.
41. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Selektive Serotoninund
Noradrenalin-Wiederaufnahmehemmer (SNRI) bei Patienten mit Depressionen.
Abschlussbericht. Auftrag A05-20A. Version 1.0. 2009 [cited: 2009 Okt 12]. Available from:
http://www.iqwig.de/download/A05-
20A_Abschlussbericht_SNRI_bei_Patienten_mit_Depressionen.pdf
42. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Bupropion,
Mirtazapin und Reboxetin bei der Behandlung der Depression. Abschlussbericht. Auftrag A05-
20C. Version 1.0. 2009 [cited: 2009 Nov 24]. Available from:
http://www.iqwig.de/download/A05-
20C_Abschlussbericht_Bupropion_Mirtazapin_und_Reboxetin_bei_Depressionen.pdf
43. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, Watanabe N,
Nakagawa A, Omori IM, McGuire H, Tansella M, Barbui C. Comparative efficacy and
acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis.
Lancet 2009;373(9665):746-58.
44. Elliott R, Greenberg LS, Lietaer G. Research on experiential psychotherapies. In: Lambert MJ,
editor. Bergin and Garfield's Handbook of Psychotherapy and Behavior Change. 5th ed. New
York: Wiley; 2004. p. 493-540
45. Roth A, Fonagy P. What Works for Whom: A Critical Review of Psychotherapy Research. New
York: Guilford; 1996.
46. Wampold BE. The great psychotherapy debate: Model, methods, and findings. Mahwah:
Erlbaum; 2001.
47. Perlis RH, Perlis CS, Wu Y, Hwang C, Joseph M, Nierenberg AA. Industry sponsorship and
financial conflict of interest in the reporting of clinical trials in psychiatry. Am J Psychiatry
2005;162(10):1957-60.
48. Gloaguen V, Cottraux J, Cucherat M, Blackburn IM. A meta-analysis of the effects of cognitive
therapy in depressed patients. J Affect Disord 1998;49(1):59-72.
49. Haby MM, Donnelly M, Corry J, Vos T. Cognitive behavioural therapy for depression, panic
disorder and generalized anxiety disorder: a meta-regression of factors that may predict
outcome. Aust N Z J Psychiatry 2006;40(1):9-19.
50. Heekerens HP. Vom Labor ins Feld. Die Psychotherapieforschung geht neue Wege.
Psychotherapeut 2005;50:357-66.
© 2009 203